Hosted on MSN6h
The New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks Therapeutics
For many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...
SpringWorks Therapeutics jumps after results, conference call cancellation
SpringWorks Therapeutics (NASDAQ:SWTX) jumped 10% in premarket trading after the firm reported its Q4 results and canceled ...
STAT9h
Risky weight loss, grad school acceptance cuts, and more major biotech news of the day
Experts noted that rapid and extreme weight loss can introduce unique risks, such as a weakened immune system and malnourishment, as well as potentially too much muscle loss. They’re also concerned ...
pharmaphorum23h
ESMO: Incyte's PD-1 treads new ground in anal cancer
Incyte's first attempt to get FDA approval for its PD-1 inhibitor Zynyz for squamous cell carcinoma of the anal canal (SCAC) was knocked back by the FDA, but new data could get the programme back ...